FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899342202> ?p ?o ?g. }

• W2899342202 endingPage "1363" @default.
• W2899342202 startingPage "1363" @default.
• W2899342202 abstract "Abstract Aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL) are rare, malignant diseases with an unfavorable prognosis. In a majority of patients, the transforming KIT mutation D816V is detectable. Currently, several drugs are available for the treatment of ASM/MCL, including midostaurin, a KIT D816V-targeting drug that has recently been approved for the treatment of advanced SM in the US and in Europe. However, when applied as single drug, midostaurin usually fails to induce durable remissions in patients with ASM/MCL, and the same holds true for all other drugs tested in the ASM/MCL context so far. Therefore, drug combinations, including established drugs and novel targeted drugs are currently being examined for their anti-neoplastic effects in ASM/MCL. CDK4 and CDK6 are kinases that play an essential role in cell cycle-initiation in normal and neoplastic cells. However, the role of CDK4/6 as potential therapeutic targets in neoplastic mast cells (MC) has not been analyzed so far. Recently, three CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib, have been translated into clinical application. The aim of the current study was to evaluate the effects of these CDK4/6 inhibitors on cell cycle progression, proliferation and survival of neoplastic MC. In initial experiments, we employed the MCL-related cell lines HMC-1.1 (lacking KIT D816V), HMC-1.2 (KIT D816V+), ROSAKIT WT, ROSAKIT D816V and MCPV-1 (expressing RAS G12V, Large T and hTert). In 3H-thymidine incorporation experiments, all three CDK4/6-inhibitors were found to block proliferation in both HMC-1 sub-clones and both ROSA sub-clones, with comparable IC50 values (<0.5 µM). In MCPV-1 cells, similar results were obtained, but higher concentrations of palbociclib, ribociclib and abemaciclib were required to block proliferation (IC50 1-5 µM). These data suggest that CDK4/6-inhibitors exert anti-proliferative effects in neoplastic MC independent of the presence of KIT D816V. In a next step, we examined drug effects on primary bone marrow cells obtained from patients with KIT D816V+ indolent SM (n=3), ASM (n=1), SM with an associated hematologic neoplasm, ASM-AHN (n=5) and MCL (n=2). As determined by 3H-thymidine uptake, palbociclib was found to inhibit cell proliferation at pharmacologically meaningful concentrations in all donors tested, with IC50 values ranging between 5 nM and 250 nM. Similar effects were obtained when applying ribociclib (25-500 nM) and abemaciclib (5-500 nM). To learn more about the mechanisms underlying the effects of the CDK4/6 inhibitors on neoplastic MC, cell cycle progression and apoptosis were examined in HMC-1.1 and HMC-1.2 cells after drug exposure. In both cell lines, the palbociclib-induced growth inhibition was found to be accompanied by cell cycle arrest in the G1-phase. Moreover, all three CDK4/6 inhibitors were found to produce time- and dose-dependent apoptosis in HMC-1.1 and HMC-1.2 cells during 72 hours of incubation. In a next step, Western blot experiments were performed using antibodies against the main downstream target of CDK6, retinoblastoma protein-1 (Rb-1). The Rb-1 antigen was found to be expressed in phosphorylated form (p-Rb-1) in HMC-1.1 and HMC-1.2 cells. As expected, all 3 CDK4/6 inhibitors were found to suppress p-Rb-1 expression in both HMC-1 cell lines, suggesting specific drug effects. In a final step, we examined potential cooperative drug effects using palbociclib and the KIT D816V-targeting drug midostaurin. In these experiments, palbociclib was found to synergize with midostaurin in inducing growth inhibition in HMC-1 cells. In conclusion our data suggest that inhibition of CDK4/6 may be a new promising approach for the treatment of patients with advanced SM. In addition, our data suggest that CDK4/6 inhibitors may represent promising combination partners for midostaurin in the treatment of ASM/MCL. Whether treatment with CDK4/6 inhibitors alone or in combination with KIT inhibition, is indeed sufficient to control proliferation of neoplastic MC in vivo in patients with advanced SM remains to be determined in forthcoming studies. Disclosures Hoermann: Novartis: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria; Pfizer: Honoraria. Sperr:Novartis: Honoraria; Pfizer: Honoraria; Daiichi Sankyo: Honoraria. Reiter:Incyte: Consultancy, Honoraria. Valent:Incyte: Honoraria; Pfizer: Honoraria; Novartis: Honoraria." @default.
• W2899342202 created "2018-11-09" @default.
• W2899342202 creator A5001718541 @default.
• W2899342202 creator A5006306448 @default.
• W2899342202 creator A5011354162 @default.
• W2899342202 creator A5021124944 @default.
• W2899342202 creator A5026124941 @default.
• W2899342202 creator A5027660853 @default.
• W2899342202 creator A5028300912 @default.
• W2899342202 creator A5040053640 @default.
• W2899342202 creator A5043288636 @default.
• W2899342202 creator A5064730399 @default.
• W2899342202 creator A5070840358 @default.
• W2899342202 creator A5072949561 @default.
• W2899342202 date "2018-11-29" @default.
• W2899342202 modified "2023-09-30" @default.
• W2899342202 title "The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest" @default.
• W2899342202 doi "https://doi.org/10.1182/blood-2018-99-116525" @default.
• W2899342202 hasPublicationYear "2018" @default.
• W2899342202 type Work @default.
• W2899342202 sameAs 2899342202 @default.
• W2899342202 citedByCount "2" @default.
• W2899342202 countsByYear W28993422022019 @default.
• W2899342202 crossrefType "journal-article" @default.
• W2899342202 hasAuthorship W2899342202A5001718541 @default.
• W2899342202 hasAuthorship W2899342202A5006306448 @default.
• W2899342202 hasAuthorship W2899342202A5011354162 @default.
• W2899342202 hasAuthorship W2899342202A5021124944 @default.
• W2899342202 hasAuthorship W2899342202A5026124941 @default.
• W2899342202 hasAuthorship W2899342202A5027660853 @default.
• W2899342202 hasAuthorship W2899342202A5028300912 @default.
• W2899342202 hasAuthorship W2899342202A5040053640 @default.
• W2899342202 hasAuthorship W2899342202A5043288636 @default.
• W2899342202 hasAuthorship W2899342202A5064730399 @default.
• W2899342202 hasAuthorship W2899342202A5070840358 @default.
• W2899342202 hasAuthorship W2899342202A5072949561 @default.
• W2899342202 hasConcept C121608353 @default.
• W2899342202 hasConcept C124320809 @default.
• W2899342202 hasConcept C126322002 @default.
• W2899342202 hasConcept C1491633281 @default.
• W2899342202 hasConcept C199649820 @default.
• W2899342202 hasConcept C203014093 @default.
• W2899342202 hasConcept C2775930923 @default.
• W2899342202 hasConcept C2776481607 @default.
• W2899342202 hasConcept C2778729363 @default.
• W2899342202 hasConcept C2779726688 @default.
• W2899342202 hasConcept C2779744173 @default.
• W2899342202 hasConcept C2780581156 @default.
• W2899342202 hasConcept C29537977 @default.
• W2899342202 hasConcept C3018593856 @default.
• W2899342202 hasConcept C502942594 @default.
• W2899342202 hasConcept C530470458 @default.
• W2899342202 hasConcept C54355233 @default.
• W2899342202 hasConcept C71924100 @default.
• W2899342202 hasConcept C86803240 @default.
• W2899342202 hasConcept C98274493 @default.
• W2899342202 hasConceptScore W2899342202C121608353 @default.
• W2899342202 hasConceptScore W2899342202C124320809 @default.
• W2899342202 hasConceptScore W2899342202C126322002 @default.
• W2899342202 hasConceptScore W2899342202C1491633281 @default.
• W2899342202 hasConceptScore W2899342202C199649820 @default.
• W2899342202 hasConceptScore W2899342202C203014093 @default.
• W2899342202 hasConceptScore W2899342202C2775930923 @default.
• W2899342202 hasConceptScore W2899342202C2776481607 @default.
• W2899342202 hasConceptScore W2899342202C2778729363 @default.
• W2899342202 hasConceptScore W2899342202C2779726688 @default.
• W2899342202 hasConceptScore W2899342202C2779744173 @default.
• W2899342202 hasConceptScore W2899342202C2780581156 @default.
• W2899342202 hasConceptScore W2899342202C29537977 @default.
• W2899342202 hasConceptScore W2899342202C3018593856 @default.
• W2899342202 hasConceptScore W2899342202C502942594 @default.
• W2899342202 hasConceptScore W2899342202C530470458 @default.
• W2899342202 hasConceptScore W2899342202C54355233 @default.
• W2899342202 hasConceptScore W2899342202C71924100 @default.
• W2899342202 hasConceptScore W2899342202C86803240 @default.
• W2899342202 hasConceptScore W2899342202C98274493 @default.
• W2899342202 hasIssue "Supplement 1" @default.
• W2899342202 hasLocation W28993422021 @default.
• W2899342202 hasOpenAccess W2899342202 @default.
• W2899342202 hasPrimaryLocation W28993422021 @default.
• W2899342202 hasRelatedWork W2552108040 @default.
• W2899342202 hasRelatedWork W2562311266 @default.
• W2899342202 hasRelatedWork W2610225211 @default.
• W2899342202 hasRelatedWork W2784856005 @default.
• W2899342202 hasRelatedWork W2888962846 @default.
• W2899342202 hasRelatedWork W2899342202 @default.
• W2899342202 hasRelatedWork W2902984185 @default.
• W2899342202 hasRelatedWork W2957984814 @default.
• W2899342202 hasRelatedWork W3020753817 @default.
• W2899342202 hasRelatedWork W4282937607 @default.
• W2899342202 hasVolume "132" @default.
• W2899342202 isParatext "false" @default.
• W2899342202 isRetracted "false" @default.
• W2899342202 magId "2899342202" @default.
• W2899342202 workType "article" @default.